Influential Russian takes a big stake in U.S. biotechs

Anatoly Chubais is one of the most influential figures in the Russian government. And he's now using his influence to invest billions of dollars in new technology through Rusnano, a move that has benefited a slate of U.S. biotechs, including Bind Biosciences and Selecta Biosciences, which are opening laboratories near Moscow. Bloomberg profiles Chubais and his plans for future investments. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.